PMID- 29412815
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20220318
IS  - 1873-5169 (Electronic)
IS  - 0196-9781 (Linking)
VI  - 100
DP  - 2018 Feb
TI  - Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the 
      incretin axis and regulation of postprandial glucose and lipid metabolism.
PG  - 158-164
LID - S0196-9781(17)30369-8 [pii]
LID - 10.1016/j.peptides.2017.11.023 [doi]
AB  - Dipeptidyl peptidase 4 (DPP4) is a widely expressed, serine protease which 
      regulates the bioactivity of many peptides through cleavage and inactivation 
      including the incretin hormones, glucagon like peptide -1 (GLP-1) and glucose 
      dependent insulinotropic polypeptide (GIP). Inhibitors of DPP4 are used 
      therapeutically to treat patients with Type 2 Diabetes Mellitus (T2DM) as they 
      potentiate incretin action to regulate islet hormone secretion and improve 
      glycemia and post-prandial lipid excursions. The widespread clinical use of DPP4 
      inhibitors has increased interest in the molecular mechanisms by which these 
      drugs mediate their beneficial effects. Traditionally, focus has remained on 
      inhibiting the catalytic activity of DPP4 within the plasma compartment, however 
      evidence is emerging on the importance of inactivation of membrane-bound DPP4 in 
      selective tissue beds to potentiate local hormone gradients. Here we review the 
      recent advances in identifying the cellular sources of both circulating and 
      membrane-bound DPP4 important for cleavage of the incretin hormones and 
      regulation of glucose and lipoprotein metabolism.
CI  - Crown Copyright (c) 2017. Published by Elsevier Inc. All rights reserved.
FAU - Mulvihill, Erin E
AU  - Mulvihill EE
AD  - University of Ottawa Heart Institute, University of Ottawa, Department of 
      Biochemistry, Microbiology and Immunology, 40 Ruskin Street, Ottawa, ON, K1Y4W7, 
      Canada. Electronic address: emulvihi@uottawa.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Peptides
JT  - Peptides
JID - 8008690
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Incretins)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/genetics/pathology
MH  - Dipeptidyl Peptidase 4/genetics/*metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Glucose/metabolism
MH  - Humans
MH  - Incretins/metabolism
MH  - Lipid Metabolism/*drug effects
MH  - Postprandial Period
OTO - NOTNLM
OT  - Dipeptidyl peptidase 4
OT  - Dyslipidemia
OT  - Glucagon like peptide 1
OT  - Glucose dependent insulinotropic polypeptide
OT  - Incretins
OT  - Soluble DPP4
OT  - Type 2 diabetes
EDAT- 2018/02/08 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/02/08 06:00
PHST- 2017/10/03 00:00 [received]
PHST- 2017/11/30 00:00 [revised]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2018/02/08 06:00 [entrez]
PHST- 2018/02/08 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - S0196-9781(17)30369-8 [pii]
AID - 10.1016/j.peptides.2017.11.023 [doi]
PST - ppublish
SO  - Peptides. 2018 Feb;100:158-164. doi: 10.1016/j.peptides.2017.11.023.